ElderlyOPTISORTNCT03666793
Comprehensive Management of Drug Prescriptions Throughout the Elderly Person's Hospital Care
A study testing global care in people with Elderly and Medication Reconciliation, run by Lille Catholic University at 1 site in France.
Trial summary
This study evaluates the impact of optimizing drug prescriptions on re-admissions of elderly patients within 30 days after hospital discharge. It compares a group of patients receiving comprehensive care (medication reconciliation at hospital entry, multidisciplinary medication review, and medication reconciliation at… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Elderly, Medication Reconciliation, Patient Readmission
- What is being tested?
- global care
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 109 participants
- Where
- 1 siteFrance
- Study dates
- 18 Sep 2018to 17 Jan 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients hospitalized in the department of short geriatric stay
Who cannot join
- Patients already included in the study, and readmitted in the same service.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comprehensive Management of Drug Prescriptions Throughout the Elderly Person's Hospital Care, From Hospital to Home: Impact on Readmission at 30 Days After Delivery
This study evaluates the impact of optimizing drug prescriptions on re-admissions of elderly patients within 30 days after hospital discharge. It compares a group of patients receiving comprehensive care (medication reconciliation at hospital entry, multidisciplinary medication review, and medication reconciliation at discharge), versus another group that does not benefit from the program.
- Conditions
- Elderly, Medication Reconciliation, Patient Readmission
- Being tested
- global care
- Keywords
- Elderly, Medication Reconciliation, Patient Readmission
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
global careOther
Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Standard healthcare procedures |
| experimental: Reconciliation group | Experimental | medical reconciliation at admission, multidisciplinary medication review, medical reconciliation at discharge of the hospital Receives: Other: global care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of readmission at 30 days
Evaluate the impact of optimizing drug prescriptions on re-admissions of elderly patients within 30 days of return to home.Only direct re-admissions to emergency and geriatric short-stay services in participating centres will be counted.
Measured: 30 days
Secondary outcomes (3)
Time between discharge and first readmission
Evaluate the impact of medication management on the time required for the first re-admission to hospital, if it takes place before 30 days.
Measured: 30 days
Rate of changes in the prescription after hospital discharge by the general practitioner
Estimate the impact of this process on the preservation of the prescription after hospital discharge by general practitioner within the 30 days following the return home actual number of discrepancies, what may have caused the change and which are the concerned drugs
Measured: 30 days
Identification of Seniors at Risk (ISAR) score
This score is based on 6 yes/no questions. T e total scale range is from 0 to 6. Each item is scored 1 if there is a problem or 0 if there is not, being the maximum score =6.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Sep 2018
- Study start18 Sep 2018
- Primary completion17 Dec 2018
- Study completion17 Jan 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ElderlyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 109 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lille Catholic University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Fabien Visade, MD, Principal investigator, GHICL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03666793
- Sponsor's protocol ID
- RC-P0069
- Acronym
- OPTISORT
- Status last verified
- Apr 2026
- First submitted
- 10 Sep 2018
- Last updated
- 20 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Visade F, Lambeaux D, Delecluse C, Decaudin B, Puisieux F, Floret E, Norberciak L, Lefebvre A. [Implementation of a multi-interventional approach to improve medication safety in older hospitalized patients: Feasibility and impact on 30-day rehospitalization rate]. Ann Pharm Fr. 2022 Jul;80(4):543-553. doi: 10.1016/j.pharma.2021.10.006. Epub 2021 Nov 4. French.
PubMed 34742917
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comprehensive Management of Drug Prescriptions Throughout the Elderly Person's Hospital Care, From Hospital to Home: Impact on Readmission at 30 Days After Delivery
- ClinicalTrials.gov ID
- NCT03666793
- Acronym / sponsor ID
- OPTISORT / RC-P0069
- Conditions
- Elderly, Medication Reconciliation, Patient Readmission
- Keywords
- Elderly, Medication Reconciliation, Patient Readmission
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 109 participants (actual)
- Lead sponsor
- Lille Catholic UniversityUniversity, hospital or other
- Study start
- 18 Sep 2018 (actual)
- Primary completion
- 17 Dec 2018 (actual)
- Study completion
- 17 Jan 2019 (actual)
- First posted
- 12 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the impact of optimizing drug prescriptions on re-admissions of elderly patients within 30 days after hospital discharge. It compares a group of patients receiving comprehensive care (medication reconciliation at hospital entry, multidisciplinary medication review, and medication reconciliation at discharge), versus another group that does not benefit from the program.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Standard healthcare procedures |
| experimental: Reconciliation group | Experimental | Other: global caremedical reconciliation at admission, multidisciplinary medication review, medical reconciliation at discharge of the hospital |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Patients hospitalized in the department of short geriatric stay
Key exclusion criteria (1 listed)
- Patients already included in the study, and readmitted in the same service.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| global careMedication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge | Other | experimental: Reconciliation group |
Primary outcome
Rate of readmission at 30 days
Time frame: 30 days
Evaluate the impact of optimizing drug prescriptions on re-admissions of elderly patients within 30 days of return to home.Only direct re-admissions to emergency and geriatric short-stay services in participating centres will be counted.
3 secondary outcomes
Time between discharge and first readmission
Time frame: 30 days
Rate of changes in the prescription after hospital discharge by the general practitioner
Time frame: 30 days
Identification of Seniors at Risk (ISAR) score
Time frame: 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2026.
- Results publication: PubMed 34742917Visade F, Lambeaux D, Delecluse C, Decaudin B, Puisieux F, Floret E, Norberciak L, Lefebvre A. [Implementation of a multi-interventional approach to improve medication safety in older hospitalized patients: Feasibility and impact on 30-day rehospitalization rate]. Ann Pharm Fr. 2022 Jul;80(4):543-553. doi: 10.1016/j.pharma.2021.10.006. Epub 2021 Nov 4. French.
Related trials for Elderly
Recruiting
Comparıson of the Effıcacy of Conventıonal Exercıse and Pılates ın Pre-fraıl and Fraıl Older Adults
Frailty Syndrome, Prefrail Elderly
RecruitingPhase 4
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Recruiting
Effects of Breathing Exercises on Cognition in Older Adults
Older Adults (65 Years and Older), Cognition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fabien Visade, MD principal investigator
GHICL
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing global care in people with Elderly and Medication Reconciliation, run by Lille Catholic University at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of readmission at 30 days (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03666793, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2026; AzTrials last refreshed its copy on 8 Nov 2026.